Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

• NASDAQ: $OCUL
• Notified: $6.15
• 07:01 EDT